SCHEDULE: MAK Capital Discloses 5.19% Stake in Standard BioTools
Beneficial Ownership Disclosure
MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman jointly reported beneficial ownership of 5.19% of Standard BioTools Inc.'s common stock.
Summary
- MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman (collectively, the "Reporting Persons") have jointly filed a Schedule 13G.
- The Reporting Persons beneficially own an aggregate of 19,967,565 shares of Common Stock of Standard BioTools Inc.
- This ownership represents 5.19% of the total outstanding Common Stock.
- The calculation of the percentage is based on 384,565,414 shares of Common Stock outstanding as of November 2, 2025, as reported by Standard BioTools Inc. in its Quarterly Report on Form 10-Q filed on November 4, 2025.
- The Reporting Persons hold shared voting power and shared dispositive power over all 19,967,565 shares.
- The securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. While a Schedule 13G is a factual disclosure, the emergence of a new institutional investor with a significant stake can be viewed favorably by the market, indicating potential confidence in the company.
Positives
- The disclosure of a 5.19% stake by an institutional investor group (MAK Capital) can be interpreted as a positive signal of confidence in Standard BioTools Inc.'s future prospects.
Future Outlook
This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding the issuer's future outlook.
Industry Context
The disclosure of a significant ownership stake by an institutional investor group like MAK Capital is a routine event in the public markets, particularly within the biotechnology and life sciences sectors where strategic investments are common. Such filings provide transparency into major shareholder positions.
Comparison to Industry Standards
- This filing is a standard regulatory disclosure (Schedule 13G) required when an entity acquires beneficial ownership of more than 5% of a company's voting class of securities. It aligns with typical reporting practices for institutional investors across all industries.
Stakeholder Impact
- Shareholders: May view the new institutional ownership as a positive indicator of investor confidence, potentially leading to increased share price stability or appreciation.
- Company Management: Awareness of a significant new shareholder may influence strategic decisions or engagement with the investor.
Key Dates
| Date | Description |
|---|---|
| 11/02/2025 | Date as of which Standard BioTools Inc. reported 384,565,414 shares of Common Stock outstanding in its Form 10-Q. |
| 11/04/2025 | Date Standard BioTools Inc. filed its Quarterly Report on Form 10-Q with the SEC. |
| 12/31/2025 | Date of event which required the filing of this Schedule 13G statement. |
| 01/07/2026 | Date as of which the shares of Common Stock were beneficially owned by the Reporting Persons and the filing date of this Schedule 13G. |
Keywords
Standard BioTools, MAK Capital, Schedule 13G, beneficial ownership, common stock, institutional investor, equity stake, biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.